Smithfield Trust Co. increased its position in shares of Zoetis Inc (NYSE:ZTS) by 63.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,067 shares of the company’s stock after buying an additional 413 shares during the period. Smithfield Trust Co.’s holdings in Zoetis were worth $107,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Cullen Frost Bankers Inc. raised its stake in shares of Zoetis by 7.5% in the first quarter. Cullen Frost Bankers Inc. now owns 321,010 shares of the company’s stock worth $32,277,000 after purchasing an additional 22,517 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Zoetis by 18.0% in the first quarter. Janney Montgomery Scott LLC now owns 148,755 shares of the company’s stock worth $14,975,000 after purchasing an additional 22,670 shares during the last quarter. UMB Bank N A MO purchased a new position in Zoetis during the first quarter valued at approximately $204,000. Osborn Williams & Donohoe LLC purchased a new position in Zoetis during the first quarter valued at approximately $191,000. Finally, Cooper Haims Advisors LLC purchased a new position in Zoetis during the first quarter valued at approximately $1,243,000. 90.95% of the stock is currently owned by institutional investors.
In other news, CEO Juan Ramon Alaix sold 312,109 shares of the company’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $94.06, for a total transaction of $29,356,972.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Catherine A. Knupp sold 32,767 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $95.80, for a total value of $3,139,078.60. Following the transaction, the insider now directly owns 82,820 shares of the company’s stock, valued at $7,934,156. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 447,975 shares of company stock worth $42,728,902. 0.29% of the stock is owned by company insiders.
Several brokerages recently weighed in on ZTS. Gabelli cut Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price target for the company. in a research report on Thursday, May 2nd. They noted that the move was a valuation call. Guggenheim began coverage on Zoetis in a research report on Thursday. They issued a “buy” rating and a $114.00 price objective for the company. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $113.00 price objective for the company in a research report on Friday, April 19th. UBS Group started coverage on Zoetis in a research report on Wednesday, March 20th. They issued a “neutral” rating for the company. Finally, BMO Capital Markets lifted their price target on Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a research note on Monday, February 25th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Zoetis currently has a consensus rating of “Buy” and an average price target of $103.93.
Shares of Zoetis stock traded down $0.49 during trading hours on Friday, hitting $102.40. The company’s stock had a trading volume of 1,254,000 shares, compared to its average volume of 2,206,161. Zoetis Inc has a twelve month low of $78.90 and a twelve month high of $104.41. The firm has a market cap of $49.27 billion, a PE ratio of 32.72, a price-to-earnings-growth ratio of 2.56 and a beta of 0.91. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.09. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.45 billion. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The company’s quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.75 EPS. As a group, equities analysts expect that Zoetis Inc will post 3.48 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 19th will be issued a $0.164 dividend. The ex-dividend date is Thursday, July 18th. This represents a $0.66 annualized dividend and a dividend yield of 0.64%. Zoetis’s dividend payout ratio is presently 21.09%.
TRADEMARK VIOLATION WARNING: “Smithfield Trust Co. Raises Holdings in Zoetis Inc (ZTS)” was first posted by Sundance Herald and is the property of of Sundance Herald. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://sundanceherald.com/2019/05/24/smithfield-trust-co-acquires-413-shares-of-zoetis-inc-zts.html.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: How prevalent are 12b-1 fees?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.